CBU
CMPX icon

CIBC Bancorp USA’s Compass Therapeutics CMPX Stock Holding History

CIBC Bancorp USA’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$37.1K Buy
+10,600
New +$33.5K ﹤0.01% 1436

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

CIBC Bancorp USA's CMPX Position: Q3 2025 in Review

CIBC Bancorp USA opened a new position in Compass Therapeutics (CMPX) in Q3 2025: 10,600 shares worth $37.1K. The stake represents ﹤0.01% of the portfolio and ranks #1436 among its holdings.

125 funds tracked by Wall St. Rank hold CMPX as of Q3 2025.

  • CIBC Bancorp USA held 10,600 shares of Compass Therapeutics worth $37.1K as of Q3 2025.
  • Compass Therapeutics was a new CIBC Bancorp USA position in Q3 2025.
  • Compass Therapeutics made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q3 2025, its #1436 holding.
  • 125 funds tracked by Wall St. Rank held Compass Therapeutics as of Q3 2025.

Based on CIBC Bancorp USA's 13F filing for Q3 2025, filed 12 Nov 2025.